Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06152731
What this trial is testing

HRD Tests for Ovarian cancER

Who this might be right for
Ovarian Cancer
Centre Francois Baclesse 88
Early research (Phase 1)Active Not RecruitingNCT05787587
What this trial is testing

PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+6 more
IDEAYA Biosciences 216
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Testing effectiveness (Phase 2)Ended earlyNCT03397394
What this trial is testing

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaMetastatic Urothelial Carcinoma+5 more
pharmaand GmbH 97
Testing effectiveness (Phase 2)UnknownNCT03337087
What this trial is testing

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Who this might be right for
Metastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma+6 more
Academic and Community Cancer Research United 18
Not applicableNot Yet RecruitingNCT07455071
What this trial is testing

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Who this might be right for
HRD-negative Epithelial Ovarian Cancer
Peking University Third Hospital 9
Testing effectiveness (Phase 2)Looking for participantsNCT04819243
What this trial is testing

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Who this might be right for
Premenopausal HR+/HER2- Metastatic Breast Cancer
Samsung Medical Center 178
Not applicableUnknownNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Testing effectiveness (Phase 2)UnknownNCT03462212
What this trial is testing

Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Who this might be right for
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 290
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Large-scale testing (Phase 3)Looking for participantsNCT06255392
What this trial is testing

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Who this might be right for
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Early research (Phase 1)Not Yet RecruitingNCT06614751
What this trial is testing

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Who this might be right for
Solid CancersBRCA MutationHRD Cancer+8 more
Danatlas Pharmaceuticals Co., Ltd 112
Testing effectiveness (Phase 2)Study completedNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07652073
What this trial is testing

DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Who this might be right for
Advanced or Metastatic Ovarian Cancer
Danatlas Pharmaceuticals Co., Ltd 30
Early research (Phase 1)Active Not RecruitingNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Varun Monga, MBBS 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT06884345
What this trial is testing

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Anhui Provincial Cancer Hospital 28
Testing effectiveness (Phase 2)Study completedNCT07162051
What this trial is testing

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Xijing Hospital 28
Early research (Phase 1)Active Not RecruitingNCT00777582
What this trial is testing

Phase I Comparative Bioavailability Study

Who this might be right for
Solid Tumors
AstraZeneca 197
Testing effectiveness (Phase 2)Study completedNCT01982448
What this trial is testing

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Dana-Farber Cancer Institute 147
Next Page